Sources checked October 25, 2026. This is a descriptive research guide, not a dose recommendation or a judgment that MSM works or is safe.
What is MSM, and is it the same as DMSO?
MSM and dimethyl sulfoxide, or DMSO, are distinct compounds.[1] The Debbi paper describes commercial synthesis of MSM from DMSO; that relationship does not make their names interchangeable.[1]
Oral MSM appeared as capsules in the Usha trial and tablets in the Toguchi trial.[4][5] The studies below concern those oral preparations, not a topical product or an injection.
What does the FDA record for MSM actually cover?
FDA's GRAS notice inventory lists methylsulfonylmethane as GRN 229, submitted by Bergstrom Nutrition.[2] It records a July 25, 2007 filing and a February 18, 2008 closure with the response "FDA has no questions".[2]
The intended uses concern specified meal-replacement foods, drinks and food bars.[2] That food-use record is not a drug-approval record or an osteoarthritis indication; it should not be presented as approval to treat arthritis.[2]
MedlinePlus distinguishes dietary supplements from drugs by noting that supplements do not undergo the same testing.[6] A supplement listing and a prescription-drug indication therefore answer different questions.[6]
What have human studies measured for MSM and knee pain?
These four reports illustrate different study designs and endpoints. Two summaries use original abstracts only, as labeled. They are not a pooled estimate, a complete systematic review or a ranking of treatments.
2004: MSM alone versus a combination
Usha and Naidu included 118 people with mild-to-moderate knee osteoarthritis in a 12-week trial comparing oral glucosamine, MSM, their combination and placebo.[4] Measures included pain, swelling, walking time, the Lequesne index and rescue-medicine use.[4]
The original abstract reports an MSM-group mean pain-index change from 1.53 to 0.74.[4] Those are within-group values, not the treatment difference versus placebo.[4] A combination-arm result cannot isolate MSM's contribution. The abstract does not supply complete arm-level attrition or missing-data methods.[4]
2006: a small placebo-controlled pilot
Kim and colleagues enrolled 50 adults aged 40 to 76 with knee osteoarthritis pain in a 12-week oral-MSM versus placebo pilot.[3] The original abstract reports statistically significant between-group differences for WOMAC pain and physical-function impairment, but no notable changes for stiffness or the aggregated symptom score.[3]
WOMAC is the Western Ontario and McMaster Universities Osteoarthritis Index.[3] The abstract also describes patient and physician assessments and the SF-36 health survey.[3] It does not provide the full outcome table or enough detail here to audit attrition.[3] A short symptom-score study is not a demonstration of long-term structural joint repair.
2011: endpoint differences and reporting caveats
Debbi and colleagues' 12-week placebo-controlled knee-osteoarthritis study reports 49 participants in its abstract but 50 assigned in its methods.[1] Assignment used alternating enrollment numbers.[1] Baseline sex, BMI and locomotor scores differed between groups.[1]
Reported between-group differences in WOMAC physical function and total score were 14.6 and 15.0 mm, respectively; WOMAC pain and stiffness comparisons were not statistically significant.[1] The authors used last-observation-carried-forward for missing follow-up values.[1] These reporting and allocation details belong beside the results, not outside them.
2023: mild knee pain is a different study population
Toguchi and colleagues randomized 88 Japanese adults with mild knee pain to oral MSM or placebo for 12 weeks.[5] People receiving treatment for knee disease were excluded.[5] The per-protocol analysis included 80 participants, 39 in the MSM group and 41 in the placebo group, rather than all 88 randomized.[5]
At week 12, the primary Japanese Knee Osteoarthritis Measure total score averaged 8.1 versus 10.9, a difference of -2.8 points (95% confidence interval -5.5 to -0.1).[5] The separate pain visual-analogue score did not differ significantly.[5] The study disclosed Chlorella Industry support.[5] Its selected mild-pain population should not be relabeled as a treated osteoarthritis cohort.[5]
What should I bring to a conversation about MSM?
MedlinePlus advises telling a health care provider about dietary supplements you use.[6] A useful discussion can start with the exact product name, a photograph of its label and a list of other products you take.
Questions to bring: Is the cited research about this ingredient alone or a blend? Is its population comparable to the question we are discussing? Which outcome was actually measured? Who can review my complete medicine and supplement list?
This page does not select a dose, prescribe a trial period or recommend replacing an existing treatment. For broader condition terminology, see the osteoarthritis guide.
Where can I compare arthritis-related clinic listings?
Regenerated.com's September 2026 export of 9,042 published clinic records includes 2,791 records tagged Arthritis Treatment across all 50 states and Washington, DC. Source: the directory's September 2026 clinic export, independently recounted for this guide on October 25, 2026. This is directory category coverage, not market size or a count of clinics confirmed to supply MSM.
If you are comparing providers for an arthritis consultation, browse the Arthritis Treatment clinic directory. Local browsing routes include Arthritis Treatment clinics in Naples, Florida and Arthritis Treatment clinics in Tampa, Florida. Confirm services directly; a category listing is not an endorsement of MSM or a treatment recommendation.